| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alberto Mella, Ester Gallo, Maria Messina, Cristiana Caorsi, Antonio Amoroso, Paolo Gontero, Aldo Verri, Francesca Maletta, Antonella Barreca, Fabrizio Fop and Luigi Biancone |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luigi Biancone, MD, PhD, Professor, Renal Transplantation Center "A. Vercellone", Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città della Salute e della Scienza Hospital and University of Turin, Corso Bramante 88, Turin 10126, Italy. luigi.biancone@unito.it |
| Key Words |
Chronic-active antibody-mediated rejection; Kidney transplantation; Donor-specific antibody; Rituximab |
| Core Tip |
Chronic-active antibody-mediated rejection (cAMR) is one of the major causes of poor long-term outcome in kidney transplantation, with no effective treatments currently available. We retrospectively compared 21 kidney transplant recipients with a diagnosis of cAMR, nine treated with plasmapheresis, intravenous immunoglobulins and rituximab vs 12 patients not treated with antibody-targeted therapies. Our data showed improvement in microvascular inflammation in post-therapy protocol biopsies without differences in functional outcomes at 24 mo, suggesting the lack of a prompt and marked effect of this therapeutic protocol. Further studies are required to improve the management and long-term results of this severe condition. |
| Publish Date |
2018-09-07 06:15 |
| Citation |
Mella A, Gallo E, Messina M, Caorsi C, Amoroso A, Gontero P, Verri A, Maletta F, Barreca A, Fop F, Biancone L. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results. World J Transplant 2018; 8(5): 178-187 |
| URL |
http://www.wjgnet.com/2220-3230/full/v8/i5/178.htm |
| DOI |
http://dx.doi.org/10.5500/wjt.v8.i5.178 |
